Regencell Bioscience Holdings Ltd

NASDAQ RGC

Data sourced from iex and EODHD
Download Data

Regencell Bioscience Holdings Ltd Gross Profit Per Share for the year ending June 30, 2023: -0.06

Regencell Bioscience Holdings Ltd Gross Profit Per Share is -0.06 for the year ending June 30, 2023, a -27.35% change year over year. Gross Profit per Share represents the gross profit allocated to each outstanding share of common stock. It provides insight into the per-share value of gross profit and is commonly used in valuation analysis. A higher value suggests a potentially more favorable investment opportunity.
  • Regencell Bioscience Holdings Ltd Gross Profit Per Share for the year ending June 30, 2022 was -0.05, a -2,119.45% change year over year.
  • Regencell Bioscience Holdings Ltd Gross Profit Per Share for the year ending June 30, 2021 was -0.00, a -178.02% change year over year.
  • Regencell Bioscience Holdings Ltd Gross Profit Per Share for the year ending June 30, 2020 was -0.00.
NASDAQ: RGC

Regencell Bioscience Holdings Ltd

CEO Mr. Yat-Gai Au
IPO Date July 16, 2021
Location Hong Kong
Headquarters First Commercial Building, Causeway Bay, Hong Kong
Employees 12
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Similar companies

EGRX

Eagle Pharmaceuticals Inc

NA

NA

PAHC

Phibro Animal Health Corporation

NA

NA

PROC

Procaps Group SA

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email